NCT06411171View on ClinicalTrials.gov

Safety and Efficacy of Pembrolizumab in Combination With FLOT About Gastroesophageal Junction Cancer:

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

June 1, 2024

Primary Completion Date

September 1, 2025

Study Completion Date

September 1, 2028

Conditions
Gastroesophageal Junction Cancer
Interventions
DRUG

Pembrolizumab plus chemotherapy (FLOT)

The experimental group was treated with pembrolizumab combined with FLOT, and the control group was treated with FLOT chemotherapy alone

All Listed Sponsors
lead

xiaohua li

OTHER